Citi raised the firm’s price target on Alnylam (ALNY) to $351 from $338 and keeps a Buy rating on the shares after the company announced that the FDA has approved its label expansion of Amvuttra to be used in the treatment of ATTR with cardiomyopathy. The drug’s label was clean and overall in line with the firm’s expectations going into the PDUFA target action date, says the analyst, who calls the approval “a significant win for Alnylam” and believes Amvuttra is “well on track to achieving mega blockbuster status.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Strategic Positioning and Market Potential Boosted by Early FDA Approval of Amvuttra
- Alnylam price target raised to $287 from $275 at Wells Fargo
- Cautious Outlook on Alnylam Pharma Amid Amvuttra’s FDA Approval and Pricing Concerns
- Buy Recommendation for Amvuttra: Strong Clinical Data and Strategic Market Positioning Drive Growth Potential
- Alnylam’s Amvuttra approved by FDA in cardiomyopathy
Questions or Comments about the article? Write to editor@tipranks.com